CASIRIVIMAB PLUS IMDEVIMAB

BRAND NAME: RONAPREVE

DRUG CLASS: Immunoglobulin (IgG1) monoclonal antibody (human), antiviral (SARS-CoV-2)

AVAILABILITY: There are **two vials** – use both to prepare the dose.
one vial contains 1332 mg/11.1 mL of casirivimab (120 mg/mL)
one vial contains 1332 mg/11.1 mL of imdevimab (120 mg/mL).[1]
The vials are labelled 20 mL, but only contain 11.1 mL.
Also contain histidine, histidine monohydrochloride monohydrate, polysorbate-80 and sucrose.[1]
The solutions are clear to slightly opalescent and colourless to pale yellow.[1]

WARNING: The occupational hazard of intermittent low dose exposure to casirivimab and imdevimab is not known. Wear a mask and gloves when preparing the infusion solution to minimise exposure.
Hypersensitivity reactions including anaphylaxis may occur. Resuscitation facilities must be readily available.[1]

pH: 6[1]

PREPARATION: Allow the vials to reach room temperature before use.
For IV infusion:[1]
Add the dose from each vial to 50–250 mL of glucose 5% or sodium chloride 0.9%.
Mix by gently inverting the bag. **Do not shake**.

For a dose of **1200 mg (casirivimab 600 mg plus imdevimab 600 mg)**:
withdraw 5 mL of casirivimab from one vial and add to the bag **and then** withdraw 5 mL of imdevimab from the other vial and add to the bag.
The total volume added to the bag is 10 mL.

For a dose of **600 mg (casirivimab 300 mg plus imdevimab 300 mg)**:
withdraw 2.5 mL of casirivimab from one vial and add to the bag **and then** withdraw 2.5 mL of imdevimab from the other vial and add to the bag.
The total volume added to the bag is 5 mL.

Dose	Volume of casirivimab		Volume of imdevimab	Total volume
1200 mg casirivimab 600 mg & imdevimab 600 mg	5 mL	**plus**	5 mL	10 mL
600 mg casirivimab 300 mg & imdevimab 300 mg	2.5 mL	**plus**	2.5 mL	5 mL

For higher doses, contact your pharmacist or medicines information service for advice.

For subcutaneous injection:[1]
Withdraw the dose into 3 mL or 5 mL syringes.
For a **1200 mg dose**, use 2 syringes of 2.5 mL each of casirivimab **plus** 2 syringes of 2.5 mL each of imdevimab. A total of 4 syringes.
For a **600 mg dose**, use 1 syringe of 2.5 mL of casirivimab **plus** 1 syringe of 2.5 mL of imdevimab. A total of 2 syringes.

CASIRIVIMAB AND IMDEVIMAB

STABILITY	Vials: store at 2 to 8 °C. Do not freeze. Protect from light.[1] Multi-dose vials only: after initial puncture, and if local protocols allow, stable for 16 hours at 25 °C or 48 hours at 2 to 8 °C.[1] Infusion solution: stable for 12 hours at 25 °C. If prepared by pharmacy under aseptic conditions, stable for 48 hours at 2 to 8 °C.[1] Prepared syringes for subcutaneous use: stable for 6 hours at 25 °C or 24 hours at 2 to 8 °C.[1] **For the first batch of stock supplied in Australia – the shelf life of the vials is 12 months**.[2]
ADMINISTRATION	
IM injection	Not recommended.
SUBCUT injection	Suitable for post-exposure prophylaxis. IV infusion is preferred for a treatment dose.[1] See PREPARATION. Inject each 2.5 mL, one after the other, into different sites. The upper thigh, upper outer arm and abdomen are suitable sites.[1]
IV injection	Not recommended
IV infusion	See PREPARATION. Infuse over 20 to 30 minutes. Use a 0.2–5 micrometre filter.[1]
COMPATIBILITY	
Fluids	Glucose 5%[1], sodium chloride 0.9%[1]
Y-site	Do not mix with other medicines
INCOMPATIBILITY	No information
SPECIAL NOTES	Monitor for possible anaphylactic and infusion reactions during the infusion and for one hour after the infusion. Infusion reactions include nausea, chills, dizziness, itching, rash and flushing and most commonly occur within 24 hours of the infusion.[1] For mild to moderate infusion reactions, slow or stop the infusion and treat accordingly.[1] Anaphylactic reactions are rare but are a medical emergency. Stop the infusion and commence treatment immediately.[1] Pain, redness and itching at the injection site are common with subcutaneous injection. Dizziness may occur.[1]

REFERENCES

1. Product information. Available from www.tga.gov.au. Accessed 04/11/2021.
2. Medical Director. Ronapreve DHPC Approved [email]. Sydney: Roche Products; 25/10/2021.
3. Medical information. Ronapreve draft guidebook [email]. Sydney: Roche Products; 25/10/2021.